Fahim Ebrahimi
Overview
Explore the profile of Fahim Ebrahimi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
595
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bergman D, Kang X, Sun J, Ebrahimi F, Ludvigsson J
J Clin Endocrinol Metab
. 2025 Mar;
PMID: 40038861
Background: Microscopic colitis (MC), comprising collagenous colitis (CC) and lymphocytic colitis (LC), is an inflammatory condition of the colon, characterized by watery diarrhoea. Previous studies suggest an association between autoimmune...
2.
Gaechter P, Ebrahimi F, Kutz A, Szinnai G
EClinicalMedicine
. 2025 Feb;
80:103062.
PMID: 39896873
Background: People with Down syndrome suffer from multiple associated diseases. However, knowledge on rates and causes of hospitalizations is limited. Methods: This population-based cohort study used national hospital claims data...
3.
4.
Vujasinovic M, Ebrahimi F, Roelstraete B, Bergman D, Sun J, Sadr-Azodi O, et al.
United European Gastroenterol J
. 2025 Jan;
PMID: 39868838
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) has been linked to pancreatic diseases, but evidence from population-based studies with liver histology is lacking. Aims And Methods: In this population-based cohort...
5.
Liao J, Chen Y, Ling Z, Purerfellner H, Martinek M, Derndorfer M, et al.
ESC Heart Fail
. 2024 Nov;
PMID: 39564882
Aims: Sodium-glucose co-transporter inhibitors (SGLTis) have cardiovascular protective effects. We aimed to assess the effects of SGLTis on individual hard clinical endpoints and quality of life (QoL) in patients with...
6.
Ebrahimi F, Ebrahimi R, Hagstrom H, Sundstrom J, Sun J, Bergman D, et al.
Circ Cardiovasc Qual Outcomes
. 2024 Nov;
17(11):e010912.
PMID: 39503614
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a risk factor for cardiovascular disease. However, whether family members of individuals with MASLD also share an increased cardiovascular risk is unknown....
7.
Ebrahimi F, Forss A
Aliment Pharmacol Ther
. 2024 Oct;
60(10):1449-1450.
PMID: 39415713
No abstract available.
8.
Sun J, Yao J, Olen O, Halfvarsson J, Bergman D, Ebrahimi F, et al.
Lancet Reg Health Eur
. 2024 Sep;
46:101056.
PMID: 39286331
Background: Co-occurrence of inflammatory bowel disease (IBD) and type 1 diabetes (T1D) has been linked to poor clinical outcomes, but evidence on their bidirectional associations remain scarce. This study aims...
9.
Ebrahimi F, Yao J, Hagstrom H, Stephansson O, Sun J, Bergman D, et al.
JAMA Netw Open
. 2024 Sep;
7(9):e2432420.
PMID: 39254974
Importance: Metabolic dysfunction-associated steatotic liver disease (MASLD) has become the most common chronic liver disease worldwide and is increasingly being diagnosed at younger ages, affecting more than one-third of young...
10.
Bergman D, Forss A, Sun J, Ebrahimi F, Ludvigsson J
Gut
. 2024 Aug;
74(3):506-508.
PMID: 39214672
No abstract available.